People

Alto adviser, Stanford psychiatry professor and director of the Stanford Mood Disorders Center. Previously chaired Stanford’s psychiatry department and served as president of several psychiatric professional societies. He is a National Academy of Medicine member and trained at Harvard and NYU.

Charles Nemeroff serves as Scientific and Medical Advisor at Engrail Therapeutics, a precision neuroscience drug-development company.

Dr. Natalie Sacks joined Venture Investments in 2022 as a Venture Partner based in the San Francisco office. Dr. Sacks is an oncologist and drug developer with over 20 years of experience in the biotechnology industry.  Prior to joining Venture Investments, she served as the Chief Medical Officer at Harpoon Therapeutics. Prior to that, she held various development and executive leadership roles at multiple companies including at Onyx Pharmaceuticals (acquired by Amgen), Aduro, Exelixis, and Cell Genesys. She has been responsible for all aspects of development ranging from initial IND to the late-stage development of commercially available oncology therapeutics. Dr. Sacks held a faculty appointment at the University of California, San Francisco for more than ten years, where she was a volunteer assistant clinical professor of medicine in the Division of Hematology/Oncology. She received her B.A. in Mathematics from Bryn Mawr College, her M.S. in Biostatistics from the Harvard University School of Public Health, and her M.D. from the University of Pennsylvania School of Medicine.

Managing partner responsible for both Arkin Bio Ventures and Arkin Bio Capital. Combines biotechnology investing with drug-development experience; joined Arkin in 2010.

Biopharmaceutical adviser to Two Bear Capital and Reunion Neuroscience board member, with former business leadership roles at Werewolf Therapeutics and Impel NeuroPharma.

Scientific adviser to BEVC; Stanford chemist and Nobel laureate in bioorthogonal chemistry. Carolyn R. Bertozzi returned to Lilly’s board in 2025 after earlier service during 2017–2021. She leads Stanford’s Sarafan ChEM-H and is a chemistry professor and Howard Hughes investigator. She studied chemistry at Harvard and Berkeley and developed foundational work in bioorthogonal chemistry.

Independent director of Immunic. Pharmaceutical executive with experience at Mineralys, Impel NeuroPharma, Nivalis and Teva, including commercial leadership in multiple sclerosis and neuroscience. Also an operating partner at Catalys Pacific.

Adam Boxer is listed by Vesper Bio as Scientific Advisor. UCSF neurologist and clinical researcher in frontotemporal dementia and neurodegenerative-disease therapeutics; current Vesper scientific-advisory affiliation is separate from existing roles.

Maurizio Fava serves as Scientific Advisory Board Member at Newleos Therapeutics, a clinical-stage neuroscience company. Maurizio Fava MD is a published external PureTech collaborator and executive vice chair of psychiatry and director of the clinical trials network and institute at Massachusetts General Hospital. His existing Newleos scientific advisory identity and portrait are preserved.

Life-sciences investor with research experience and a biology PhD from the Max Planck Society; biotechnology degrees from IIT Madras.

Clifford Woolf co-founded QurAlis and serves on its scientific advisory board. His research spans neural mechanisms of pain, neurodegeneration and patient-derived stem-cell disease models; his career includes University College London, Harvard and Boston Children’s Hospital after medical and doctoral training at the University of the Witwatersrand.

Myrobalan scientific co-founder and board adviser, and a Harvard Medical School professor of neurology and ophthalmology. Studies axon regeneration, neurodegeneration and remyelination. Holds a University of Toronto PhD and completed postdoctoral research at UCSF. Also a scientific adviser to Axonis Therapeutics.

Brock Reeve was named by Bioverge’s own 2023 Republic corporate offering as External Advisor. The campaign explicitly includes people helping build Bioverge beyond employees. This establishes a dated platform affiliation, with current tenure, formal employment and any personal investment not inferred.

Raymond J. Kelleher is managing director of Cormorant Asset Management, a position its current roster confirms and a 2026 issuer proxy dates to July 2020. He practices neurology at Massachusetts General Hospital with a focus on Alzheimer’s disease and related dementias. He trained at MIT and Stanford, earning an MD and PhD. The issuer dates his Harvard assistant professorship from July 2005 to October 2023; it is a former appointment. His investment and clinical roles are distinct from personal cash investments.

Biopharmaceutical research and development leader and CTI Life Sciences Fund managing partner; serves on Aeovian Pharmaceuticals’ board.

Amplitude co-founder and managing partner with prior life-sciences investment leadership at BDC Capital and CDPQ and experience founding biotechnology companies.

Feldan Therapeutics board member and chair and chief executive of Thryv Therapeutics, identified in the current Feldan biography. Earlier founded and led Anthera Pharmaceuticals and Peninsula Pharmaceuticals. His education includes an MBA from Indiana University and an economics degree from the University of Waterloo.

Neurologist and Head of Medical at Clene, concurrently Vice Chair of Clinical and Translational Research in neurology at UT Southwestern. His work includes multiple sclerosis and rare neurological disorders; he also advises Arialys Therapeutics.

Johnson & Johnson Innovation–JJDC venture investor focused on new company creation. TRexBio director as of October 5, 2026, with resignation planned before IPO registration effectiveness; previously worked at Quaker Partners and in J&J research, operations and venture creation.

Nadiya Ishnazarova is a TRIMTECH non-executive director and senior venture investor at Johnson & Johnson Innovation–JJDC. She previously invested in biotechnology at M Ventures and advised healthcare clients at Oliver Wyman. She holds an Oxford biochemistry doctorate and earlier chemistry and biotechnology qualifications from Moscow State University.

Martin J. Emerson is President and Chief Executive Officer at Monteris Medical. Known as Marty Emerson, he has led the company since 2016 and also serves on its board.

Joined the Charles River board in May 2025. Led ImmunoGen from 2016 until its acquisition by AbbVie in 2024 and previously worked at Shire and Genzyme.

Deep Track Capital managing director and Draig Therapeutics board observer. Also serves on Imbria Pharmaceuticals' board and has healthcare investment experience at New Leaf Venture Partners.

Albert Kim holds the source-published role of Advisor within RA Capital Management’s Raven group. Published academic qualifications: MD , PhD. Universities identified in the own biography: Harvard University, University of California Los Angeles. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Nimbus Therapeutics director with biotechnology venture investment, drug development and business experience at SR One, GSK, Genentech and Bio-Rad Laboratories.

Ken joined Venture Investments (US) Inc. in San Francisco, California in 2015. Ken brings experience as a Senior Market Planning Manager at Genentech, where he helped guide strategic decision making for the Ophthalmology and HER2 franchises. Prior to Genentech, Ken worked as a management consultant at L.E.K. Consulting and as the Entrepreneurship Program Manager at QB3/Mission Bay Capital, where he helped create new programs to launch and support life sciences companies in the Bay Area. Ken studied cellular lipid storage and metabolism as an A.P. Giannini Foundation Fellow at the J. David Gladstone Institutes, earned a PhD in Pharmacology from Yale University, and has a BS in Molecular Biology from Texas Tech University, where he was a Howard Hughes Medical Institute undergraduate research fellow.

Seth Fischer is listed by HealthQuest Capital as Industry Advisory Board Member. The directory describes their outside context as Former Company Group Chairman Johnson & Johnson; this is not an executive title at HealthQuest. The primary biography explicitly identifies Seth H. Z. Fischer, the Johnson & Johnson veteran and Catalys Pacific partner, distinct from Oasis founder Seth Fischer.

Timothy (Tim) Walbert is a senior adviser to Patient Square Capital, managing partner of HRZN Partners and adviser to Amgen. He previously led Horizon Therapeutics and IDM Pharma and serves as independent board chair of Crystalys Therapeutics.

Barry Greene serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor.

John Maraganore serves as Strategic Advisory Board Member at Longwood Fund, a biotechnology company builder and life sciences venture investor. He also advises Magnetic Ventures, according to its current team directory. John Maraganore joined Takeda’s board as an external director in June 2022. He previously led Alnylam and held strategic development leadership at Millennium Pharmaceuticals. His current professional roles include JMM Innovations and Corsera Health, alongside biotechnology boards and advisory work. John Maraganore became an Omega Advisor and Venture Partner in September 2022. He was founding Chief Executive Officer of Alnylam from 2002 to 2021, following roles at Millennium, Biogen, ZymoGenetics and Upjohn. His scientific degrees include a University of Chicago doctorate.

Andrew Levin holds the source-published role of Advisor within RA Capital Management’s Healthcare group. The individual directory reports joining in2026; a precise appointment day is not available. Published academic qualifications: MD , PhD. Universities identified in the own biography: Princeton University, Massachusetts Institute of Technology, Harvard Medical School. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

ArrePath board member and Insight Partners managing director focused on computational biology. Previously a CRV general partner and investor at Innovation Endeavors, and co-founded Integrated Plasmonics. Studied computer science at Harvard and conducted graduate research in biochemistry and molecular biophysics at Caltech. Insight Partners source, reviewed October 8, 2026: I believe in remote human possibilities and the almost infinite potential of the individual. To me, it’s clear that people matter most of all. I’ve always wanted to understand how the mind works. In college, I studied computational neuroscience, worked in a primate cognition lab, and graduated with a degree in computer science. My first real job was writing software to simulate computer networks. It was amazing to me how well simulation works, that you can create a faithful representation of a system, simulate its dynamics, and learn meaningful things about the real live system. If this works so well for computer networks (and bridges, airplanes, autonomous vehicles, etc.), why shouldn’t it work for biology? This question and the desire to simulate biological systems led me to Caltech, where I enrolled in a biophysics PhD program. I worked in an early cryo-EM lab where we looked at the simplest cells in 3D. I built computational models to simulate tiny pieces of these cells. The work was fascinating but disconnected from the realities of the human condition. Academic science is slow and careful. While professors compete for limited resources, people are dying. I began to realize the best way for me to have an impact and help people is to accelerate biomedical innovation. My desire to make the future happen faster is how I discovered startups. Shortly after, I left grad school (with some papers, but no degree) and started a biosensor company with a couple of friends. We raised funding from great investors and hired the most talented scientists and engineers, however we ultimately failed. Democratizing diagnostics is a worthwhile mission, but a challenging business. From there, I found my way into investing and it’s a perfect fit. Backing brilliant founders who are innovating at the forefront of biomedicine feels like a force multiplier for good. I began my venture career at Innovation Endeavors, investing at the intersection of data science and life science. After that, I worked at CRV and helped build the firm’s bioengineering practice. I came to Insight in July 2021 to lead our emerging efforts in the bio space. My team and I love technology-enabled approaches to drug discovery and development, new therapeutic modalities, and especially curative therapies. Bring us your wildest ideas but show us how you will reduce them to practice. We’re here and ready to listen.